Background {#Sec1}
==========

Chemotherapy- induced peripheral neuropathy (CIPN) is one of the major dose-limiting side effects of many chemotherapeutic agents including platinum analogues, vinca alkaloids, and taxanes \[[@CR1]\]. The structure and function of peripheral motor, sensory and autonomic neurons are affected, causing peripheral neuropathic signs and symptoms \[[@CR2]\]. In a systematic review of 31 studies (*N* = 4179), CIPN prevalence was 68.1% at the first month of chemotherapy to 30% six-months after chemotherapy, with wide variance in prevalence from 12.1--96.2%, depending on different timings of assessment and type of chemotherapy, and many assessing CIPN as part of a drug trial or with studies being cross-sectional \[[@CR3]\].

What is already known is that neuropathic symptoms tend to progress during chemotherapy and generally regress once treatment stops; symptoms can consist of a mixture of motor, sensory, and autonomic signs; and the pain associated with CIPN can be prolonged and severe, and its treatment is usually difficult \[[@CR3]--[@CR5]\]. Furthermore, neuropathy can have a negative impact on patient's quality of life \[[@CR4]\]. Studies showed that CIPN is associated with fatigue, psychological distress and decline in physical independence \[[@CR6]--[@CR10]\]. CIPN may have an impact on the patients' ability to work \[[@CR11]\] and is associated with significantly higher medical costs (\$17,344 more/patient) and higher healthcare utilization than non-CIPN patients \[[@CR12]\].

It is clear in the literature that the assessment of CIPN is suboptimal \[[@CR6]\]. A recent study using a Delphi technique in a small number of clinicians and consumers showed that there is no consensus as to the best assessment method for CIPN \[[@CR13]\]. The NCI Common Toxicity Criteria (CTC) assessment for neuropathy may overestimate the presence of motor neuropathy and misdiagnose CIPN \[[@CR14]\], although a consensus meeting suggested that the NCI CTC has good intra/interrater scores and validity \[[@CR15]\]. Haryani et al. \[[@CR16]\] reviewed available scales and suggested that the FACT-COG-Ntx scale and the Total Neuropathy Scale (TNS) as psychometrically optimal scales out of 20 tools examined. In another study, the Patient Neurotoxicity Questionnaire (PNQ) and the TNS were recommended \[[@CR13]\]. The PNQ in particular seems to have received extensive evaluation in response to identified assessment problems with high variance and lack of reliability and concordance of past scales \[[@CR1], [@CR17]--[@CR20]\], and was recommended as a patient-reported outcome preferred tool by another study \[[@CR13]\]. It is also clear that there is a significant discrepancy between clinician-rated CIPN through available tools and patient-reported outcome scales, with clinicians under-estimating the severity of CIPN \[[@CR19]\]. Another study showed that EORTC-CIPN20 scores may not be reliably converted to CTCAE scores \[[@CR21]\]. While the NCI CTC score is generally considered unreliable \[[@CR6]\], it has shown significant correlations with the more accepted and reliable TNS \[[@CR22]\]. There are multiple studies on this topic, all providing different and often contradictory views on the most appropriate CIPN assessment method, with no 'gold standard' consensus being reached yet.

Longitudinal studies to systematically determine the incidence, severity and natural history of CIPN with different neurotoxic chemotherapy drugs are vital in order to quantify the extent of the problem and inform future design of interventional studies; such studies are uncommon in the literature \[[@CR23]\]. Also, prevalence may be linked with the particular assessment scale used in each study, and the sensitivity of scales to detect CIPN is variable in the literature. While some assessment tools have received significant attention in the literature (most with variable reliability/validity issues as mentioned above), there may be other tools that can be utilised in the assessment of CIPN and have received minimal attention that are however used in other areas of medicine effectively (ie. in assessing diabetic neuropathy, etc). Hence, the present study aims to identify the natural history and progression of CIPN within different chemotherapy drugs for up to 12 months after the patient's first infusion of chemotherapy and to analyse consistency of different assessment methods, including the introduction of some more novel approaches in CIPN assessment in detecting prevalence.

Methods {#Sec2}
=======

Design {#Sec3}
------

Multinational prospective longitudinal observational cohort study over 12 months from the patient's first neurotoxic chemotherapy infusion.

Sample and settings {#Sec4}
-------------------

The sample included a heterogeneous group of consecutive patients receiving neurotoxic chemotherapy as inpatients or outpatients in three large hospitals in Hong Kong, Singapore, and Manchester, UK.

Inclusion criteria {#Sec5}
------------------

Cancer patients who are neurotoxic chemotherapy-naïve and about to receive taxane- and/or platinum-based chemotherapyestimated survival of at least 12 months (as judged by the clinicians)aged 18+ yearsable to give written informed consent

Sampling and procedures {#Sec6}
-----------------------

Eligible patients were identified by convenient sampling and were approached at the outpatients' clinics by a designated researcher consecutively if they met inclusion criteria. Patients were provided with detailed information about the study. Those who agreed to participate and provided signed consent completed all the baseline measurements and CIPN toxicity assessment at different time intervals. The researchers who carried out the toxicity assessments had undertaken training in neurological assessments beforehand and were provided with a set of standardized guiding questions regarding the grade of toxicity, in order to maintain consistency. Clinical data were obtained from the patients' medical records. The study was approved by all participating hospitals and their respective ethics committees.

Outcome measures {#Sec7}
----------------

All assessments were carried out at baseline, at the end of each chemotherapy cycle (before or on day 1 of each chemotherapy cycle) for up to six cycles, and at 6, 9 and 12 months after enrollment into the study.

The NCI-CTCAE is a clinician-based grading system that includes criteria and definitions for quantifying the severity of CIPN in both sensory and motor components, utilizing a 5-point scale \[grade 1 (asymptomatic) to grade 5 (death)\]. A score of \>/=2 was deemed indicative of CIPN.

The WHO-CIPN criterion is also a clinician-based grading system, which includes paresthesias, reflex decreases and extent of motor loss as parameters \[[@CR24]\], with scores from 0 (none) to 4 (paralysis). A score of \>/=1 was deemed indicative of CIPN.

Additionally, a neurological examination (deep tendon reflexes; pin sensation; strength) supplemented with a list of questions as mentioned earlier were also used to derive to the scoring of the above two scales.

Sensory examination was conducted by a research team member using: a) cotton wool to lightly touch the patient's hands and feet bilaterally with the patients eyes closed at five points in each limb and b) 10 g monofilament test in five points in each limb which is a commonly used test in detecting diabetic neuropathy \[[@CR25]\]. Hypo/hyperesthesia in most points touched was deemed indicative of CIPN.

Patient-reported outcome measures: For the current analysis, only the four items on numbness/tingling in hands/feet were used from the neuropathy modules of: a) The Functional assessment of cancer therapy (FACT/GOG-Ntx) \[[@CR26], [@CR27]\]. b) The EORTC-QLQ-C30 with its CIPN20 module \[[@CR28]\].

Of the main study cohort, a sub-group of patients consented to nerve conduction studies (NCS) as a mode of measurement of CIPN. Each patient underwent NCS of the upper and lower limbs for assessment of neuropathy at three time points: before (NCS~baseline~), at the end of treatment (NCS~end~) and 3 months post-treatment (NCS~3m~). Sensory nerve action potential (SNAP) amplitudes and conduction velocities were measured in the bilateral medial, ulnar and radial nerves \[[@CR29]\]. Compound motor action potential (cMAP) amplitudes and motor nerve conduction velocities were evaluated in the bilateral sural, saphenous, superficial peroneal, common peroneal and tibial nerves \[[@CR30]\].

Data analysis {#Sec8}
-------------

Descriptive statistics were used to summarise the data. Prevalence estimates were calculated using 95% CIs of the percentage of patients with CIPN. Spearman correlations were used to examine the interrelationships among CTCAE-sensory, CTCAE-motor, monofilament, and WHO criterion. The dose-response relationships between cumulative chemotherapy dose and CIPN were visualized using restricted cubic splines, and the exact dose-response equations were estimated using segmented regression models. The dose-response relationship analysis was performed using R3.3.0 and the remaining statistical analysis was performed using SPSS v.23.0.

Results {#Sec9}
=======

Sample characteristics {#Sec10}
----------------------

The sample included 343 patients being assessed up to a maximum of 10 times over 12 months (total = 2399 assessments); 213 were recruited from Hong Kong, 94 from Singapore and 36 from Manchester, UK. They were at a mean age of 55.15 years old (SD = 9.4; range = 33--79). Furthermore, 33 subjects completed the NCS~baseline~ and NCS~end~ assessments, out of which 22 also completed the NCS~3m~. Among the patients who completed the NCS, 28 were female (85%), at a median age of 54 years and were receiving primarily Taxol (85%) and platinum-based chemotherapy (15%). Other overall sample characteristics are shown in Table [1](#Tab1){ref-type="table"}.Table 1Socio-demographic and clinical characteristics of the participants (*N* = 343)CharacteristicN%Sex Male8725.4 Female25674.6Ethnicity Chinese26978.4 Non-Chinese Asian319.0 Caucasian4312.5Cancer diagnosis Breast cancer17450.7 Lung cancer4814.0 Gynecological cancer4613.4 Head & Neck cancer308.7 Gastrointestinal cancer298.5 Urinary tract cancer164.7Cancer stage I5215.2 II9928.9 III11633.8 IV7622.2Treatment intent Curative25072.9 Definitive308.7 Palliative6318.4Type of chemotherapy Taxane15545.2 Platinum10931.8 Combination of taxane plus platinum7923.0Chemotherapy protocol Docetaxel12235.6 Paclitaxel339.7 Cisplatin/Carboplatin8023.4 Oxaliplatin288.3 Carboplatin+Paclitaxel4914.4 Carboplatin+Docetaxel298.6

Prevalence of CIPN {#Sec11}
------------------

CIPN prevalence rates identified by different measurement tools varied significantly, and occurrence of CIPN peaked at different times. CIPN peak prevalence rates were 17.5% for the CTCAE motor criterion and 14.2% for the CTCAE sensory criterion at cycle 6; 30.3% for the WHO criterion at cycle 5; 13.4% for the cotton wool test at 6-month follow-up; 19.4% for the monofilament test at 6-month follow-up; 44.9--53.4% for the EORTC-CIPN20 items at cycle 6, and 46.3--49.6% at cycle 6 and 6-month follow-up (Table [2](#Tab2){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). Motor symptoms were slightly more frequently reported than sensory symptoms (as per CTCAE).Table 2Chemotherapy-induced peripheral neuropathy prevalence by different measures over time (*N* = 343)MeasuresBaselineCycle1Cycle2Cycle3Cycle4Cycle5Cycle66mFU9mFU12mFUn/N%n/N%n/N%n/N%n/N%n/N%n/N%n/N%n/N%n/N%NCI motor^1^ Grade 1338/34199.1294/30895.5273/29094.1244/27389.4209/24286.4121/14285.299/12082.5219/25585.9204/23487.2177/19491.2 Grade \> =23/3410.914/3084.517/2905.929/27310.633/24213.621/14214.8**[21/120]{.ul}[17.5]{.ul}**36/25514.130/23412.817/1948.8 *Grade 2*3/3410.914/3084.516/2905.525/2739.228/24211.617/14212.018/12015.026/25510.225/23410.714/1947.2 *Grade 3*1/2900.44/2731.55/2422.14/1422.83/1202.510/2553.95/2342.13/1941.6NCI sensory^1^ Grade 1340/34199.7297/30896.4273/29094.1254/27393.0222/24291.7126/14288.7103/12085.8222/25587.1205/23388.0178/19491.8 Grade \> =21/3410.311/3083.617/2905.919/2737.020/2428.316/14211.3**[17/120]{.ul}[14.2]{.ul}**33/25512.928/23312.016/1948.2 *Grade 2*1/3410.311/3083.616/2905.513/2734.817/2427.014/1429.916/12013.328/25511.026/23311.214/1947.2 *Grade 3*1/2900.46/2732.23/2421.22/1421.41/1200.85/2552.02/2330.82/1941.0WHO CIPN ^2^ Grade 0333/34197.7277/30889.9248/29085.5217/27379.5182/24275.299/14269.797/12080.8210/25582.4197/23484.2180/19492.8 Grade \> = 18/3412.331/30810.142/29014.556/27320.560/24224.8**[43/142]{.ul}[30.3]{.ul}**23/12019.245/25517.637/23415.814/1947.2 *Grade 1*8/3412.325/3088.137/29012.849/27317.953/24221.939/14227.521/12017.540/25515.733/23414.112/1946.2 *Grade 2*5/3081.63/2901.06/2732.27/2422.93/1422.12/1201.65/2552.04/2341.72/1941.0 *Grade 3*1/3080.32/2900.71/2730.41/1420.7Cotton wool Normal (−)306/30799.7268/27996.1257/26796.3237/25792.2203/21295.8124/13591.9100/10793.5188/21786.6163/18389.1138/14396.5 Abnormal (+)1/3070.311/2793.910/2673.720/2577.89/2124.211/1358.17/1076.5**[29/217]{.ul}[13.4]{.ul}**20/18310.95/1433.5 *A lot of sensation*4/2791.48/2673.02/2570.83/1072.83/2171.46/1833.31/1430.7 *A bit sensation*1/3070.31/2790.41/2670.42/2570.82/2120.91/1350.721/2179.712/1836.64/1432.8 *No sensation*6/2792.21/2670.416/2576.27/2123.310/1357.44/1073.75/2172.32/1831.1Monofilament Normal (−)306/30799.7290/30296.0272/29093.8246/27390.1198/22090.0121/14285.292/10686.8187/23280.6162/19682.7137/14793.2 Abnormal (+)1/3070.312/3024.018/2906.227/2739.922/22010.021/14214.814/10613.2**[45/232]{.ul}[19.4]{.ul}**34/19617.310/1476.9 *A lot of sensation*2/3020.73/2901.04/2731.52/2200.94/1422.85/2322.29/1964.62/1471.4 *A bit sensation*1/3070.35/3021.78/2902.811/2734.014/2206.49/1426.39/1068.533/23214.221/19610.77/1474.8 *No sensation*5/3021.77/2902.412/2734.46/2202.78/1425.65/1064.77/2323.04/1962.11/1470.7ECIPN-20 ^3^ Numbness in hands/fingers *Grade 1*286/34283.6232/30675.8198/28769.0176/27164.9144/24060.082/13859.455/11846.6142/25555.7146/23462.4134/19568.8 *Grade \> =2*56/34216.474/30624.289/28731.095/27135.196/24040.056/13840.6**[63/118]{.ul}[53.4]{.ul}**113/25544.388/23437.661/19531.2 *Grade 2*50/34214.655/30618.062/28721.672/27126.666/24027.536/13826.136/11830.573/25528.667/23428.649/19525.1 *Grade 3*5/3421.512/3063.921/2877.316/2715.921/2408.814/13810.119/11816.127/25510.616/2346.89/1954.6 *Grade 4*1/3420.37/3062.36/2872.17/2712.69/2403.86/1384.38/1186.813/2555.15/2342.13/1951.5Numbness in feet/toes *Grade 1*308/34389.8244/30779.5217/28775.6188/27169.4146/24060.881/13858.765/11855.1142/25555.7148/23563.0138/19570.8 *Grade \> =2*35/34310.263/30720.570/28724.483/27130.694/24039.257/138[41.3]{.ul}**[53/118]{.ul}[44.9]{.ul}**113/25544.387/23537.057/19529.2 *Grade 2*31/3439.049/30716.047/28716.462/27122.965/24027.137/13826.836/11830.573/25528.663/23526.841/19521.0 *Grade 3*2/3430.610/3073.316/2875.612/2714.422/2409.213/1389.412/11810.229/25511.416/2356.811/1955.6 *Grade 4*2/3430.64/3071.37/2872.49/2713.37/2402.97/1385.15/1184.211/2554.38/2353.45/1952.6FACTGOG-Ntx ^4^Numbness/tingling in hands *Grade 0*296/34386.3235/30776.5194/28767.6178/27165.7144/24060.075/13854.360/11950.4139/25554.5148/23563.0137/19570.3 *Grade \> =1*47/34313.772/30723.593/28732.493/27134.396/24040.063/13845.7**[59/119]{.ul}[49.6]{.ul}**116/25545.587/23537.058/19529.7 *Grade 1*39/34311.442/30713.757/28719.961/27122.561/24025.436/13826.133/11927.765/25525.561/23526.037/19519.0 *Grade 2*4/3431.217/3075.512/2874.210/2713.715/2406.38/1385.814/11911.818/2557.19/2353.88/1954.1 *Grade 3*2/3430.69/3072.912/2874.211/2714.114/2405.812/1388.77/1195.920/2557.811/2354.79/1954.6 *Grade 4*2/3430.64/3071.312/2874.211/2714.16/2402.57/1385.15/1194.213/2555.16/2352.64/1952.1*Numbness/tingling in feet* *Grade 0*317/34392.4247/30780.5215/28774.9183/27167.5146/24060.879/13857.270/11859.3137/25553.7150/23563.8143/19573.3 *Grade \> =1*26/3437.660/30719.572/28725.188/27132.594/24039.259/13842.848/11840.7**[118/255]{.ul}[46.3]{.ul}**85/23536.252/19526.7 *Grade 1*17/3435.035/30711.444/28715.358/27121.465/24027.135/13825.430/11825.469/25527.154/23523.034/19517.4 *Grade 2*6/3431.712/3073.910/2873.59/2713.313/2405.45/1383.69/1187.622/2558.613/2355.57/1953.6 *Grade 3*2/3430.67/3072.310/2873.511/2714.110/2404.213/1389.46/1185.117/2556.79/2353.89/1954.6 *Grade 4*1/3430.36/3072.08/2872.810/2713.76/2402.56/1384.33/1182.510/2553.99/2353.82/1951.0^1^NCI sensory/motor grading (Grade 1 = Asymptomatic not interfering with functioning, Grade 2 = Moderate symptoms limiting instrumental ADL, Grade 3 = Severe symptom limiting self care ADL; assistive device indicated); ^2^ WHO CIPN grading (Grade 0 = None, Grade 1 = Paresthesias and/or decreased tendon reflexes, Grade 2 = severe paresthesias and/or mild weakness, Grade 3 = intolerable paresthesias and/or marked motor loss); ^3^ ECIPN-20 grading (Grade 1 = not at al, Grade 2 = a little, Grade 3 = quite a bit, Grade 4 = very much); ^4^ FACT GOG-Ntx grading (Grade 0 = not at all, Grade 1 = a little bit, Grade 2 = somewhat, Grade 3 = quite a bit, Grade 4 = very much). Bold font and underlined numbers indicate the highest prevalence of peripheral neuropathy for each measure usedFig. 1Chemotherapy-induced peripheral neuropathy prevalence by different measures over 1-year period

In the taxane-based group, there was a sharp increase soon into the 3rd-5th chemotherapy cycles, and rates remained high across subsequent follow-up, with only a noticeable decrease at the 12-month follow-up (Fig. [2](#Fig2){ref-type="fig"}). and peak rates ranging, depending on the scale used, from 13.1% (cotton wool; 9MFU), 19.5% (CTCAE-sensory, 6MFU), 20.3% (CTCAE-motor, 6MFU), 32.2% (WHO, cycle5), 43.1--47.2% (FACT/COG-Ntx, 6MFU) to 42.3--54.9% (EORTC, cycle 6 & 6MFU). In the platinum-based group, CIPN levels were relatively low, often being established very early (cycles 2--3) (Fig. [3](#Fig3){ref-type="fig"}). In the combination groups, noticeable increases were around cycles 3--6, decreasing significantly after the 6-month follow-up (Fig. [4](#Fig4){ref-type="fig"}). Severe CIPN scores (ie. \>/=3 in CTCAE; \>/=2 in WHO scale) accounted for a very small number (highest 3.9%) of patients at 6-month follow-up, although this was up to 22.9% at cycle 6 using the EORTC-CIPN20 numbness item (hands/fingers).Fig. 2Chemotherapy-induced peripheral neuropathy (with 95% CIs) over time and with different measures used in patients receiving taxanesFig. 3Chemotherapy-induced peripheral neuropathy (with 95% CIs) over time and with different measures used in patients receiving platinum chemotherapyFig. 4Chemotherapy-induced peripheral neuropathy (with 95% CIs) over time and with different measures used in patients receiving combination chemotherapy with taxanes and platinum

Within chemotherapy categories, different chemotherapy types produced differential neurotoxicity. In the taxane group, motor dysfunction was more prevalent in the docetaxel subgroup with a steady increase over cycles, with highest prevalence at 9 months (21.3%), whereas the paclitaxel subgroup showed significantly lower prevalence (Table [3](#Tab3){ref-type="table"} & Fig. [5](#Fig5){ref-type="fig"}a-f). The opposite was true for sensory dysfunction, where the paclitaxel subgroup had substantially higher rates of sensory problems than the docetaxel subgroup, and at times of certain assessments the difference was 5--10 times more (Table [3](#Tab3){ref-type="table"} & Fig. [5](#Fig5){ref-type="fig"}a-f). When paclitaxel was combined with carboplatin, again the rates of CIPN were significantly higher in this subgroup than docetaxel plus carboplatin (Table [3](#Tab3){ref-type="table"} & Fig. [5](#Fig5){ref-type="fig"}a-f). The prevalence varied significantly from scale to scale used for the assessment. From the clinician-based assessment (supplemented by neurological examination), highest prevalence was identified with the WHO-CIPN item followed by the use of monofilament. The patient-reported outcome measures showed significantly higher prevalence than any clinician-based measures; to note, these scales, unlike the clinician-based ones, also showed a considerable number of patients who reported symptoms indicative of CIPN at the baseline assessment (3.2--21.4%) (Table [3](#Tab3){ref-type="table"} & Fig. [5](#Fig5){ref-type="fig"}a-f). Looking at the PRO descriptors of CIPN (using the 9-month assessment, with all other assessments being very similar), typically patients with paclitaxel or oxaliplatin had a higher incidence than other protocols in terms of tingling in the hands/fingers (42.9 and 47.1% respectively vs 3.6--14.4%); tingling in the feet/toes (42.9 and 52.9% respectively vs 0--15.6%); burning pain in hands/feet/fingers/toes (23.8 and 23.5% respectively vs 0--9.5%); dizziness (19 and 17.6% respectively vs 3.6--8.9%); or blurred vision (38.1 and 35.3% respectively vs 10.7--27.8%). Cramps in the hands were more common in the carboplatin/cisplatin subgroup (19 and 23.5% respectively) while cramps in the feet were more common in the paclitaxel (28.6%) and oxaliplatin (29.4%) subgroup. Hearing problems were reported more often in the cisplatin/carboplatin subgroup (28.6%). Maintaining erection was reported primarily by the docetaxel subgroup (85.7%) and carboplatin/cisplatin subgroup (50%).Table 3Chemotherapy-induced peripheral neuropathy prevalence by 6 different chemotherapy drugsCIPN measuresSamplesBaselineCycle1Cycle2Cycle3Cycle4Cycle5Cycle66mFU9mFU12mFUn/N (%)N (%)N (%)N (%)N (%)N (%)N (%)N (%)N (%)N (%)NCI motor ^1^\
(\> = grade2)Docetaxel2/122 (1.6)3/122 (2.7)4/109 (3.7)13/105 (12.4)21/95 (22.1)9/41 (22)8/38 (21.1)20/96 (20.8)19/89 (21.3)12/84 (14.3)Paclitaxel0/33 (0)3/33 (9.1)2/31 (6.6)2/31 (6.4)0/28 (0)0/13 (0)1/13 (7.7)5/27 (18.5)3/21 (14.3)1/15 (6.7)Cisplatin/Carboplatin1/80 (1.2)2/65 (3.1)5/57 (8.8)6/46 (13)4/32 (12.5)1/9 (11.1)0/6 (0)3/43 (7)3/39 (7.7)2/32 (6.2)Oxaliplatin0/28 (0)2/26 (7.7)2/25 (8)0/22 (0)0/22 (0)0/16 (0)1/11 (9.1)1/21 (4.8)0/17 (0)0/12 (0)Carboplatin+paclitaxel0/49 (0)3/44 (6.8)2/42 (4.8)6/42 (14.3)6/38 (15.8)6/30 (20)5/24 (20.8)14/24 (58.3)5/40 (12.5)2/24 (8.3)Carboplatin+docetaxel0/29 (0)1/28 (3.6)2/26 (7.7)2/27 (7.4)2/27 (7.4)5/26 (17.9)6/28 (21.4)1/28 (3.6)0/28 (0)0/27 (0)NCI sensory^1^\
(\> = grade2)Docetaxel0/122 (0)1/122 (0.9)4/109 (3.7)7/105 (6.7)10/95 (10.5)5/41 (12.2)4/38 (10.5)17/96 (17.7)17/89 (19.1)9/84 (10.7)Paclitaxel0/33 (0)3/33 (9.1)3/31 (9.7)2/31 (6.14)0/28 (0)0/18 (0)3/13 (23.1)7/27 (25.9)4/21 (19)2/15 (13.4)Cisplatin/Carboplatin1/80 (1.2)0/65 (0)4/57 (7.0)4/46 (8.7)2/32 (6.3)1/9 (11.1)0/6 (0)2/43 (4.7)3/39 (7.7)2/32 (6.2)Oxaliplatin0/28 (0)2/26 (7.7)2/25 (8)0/22 (0)0/22 (0)0/16 (0)1/11 (9.1)1/21 (4.8)1/17 (5.9)0/12 (0)Carboplatin+paclitaxel0/49 (0)5/44 (11.4)3/42 (7.1)5/42 (11.9)7/38 (18.4)7/30 (23.3)7/27 (29.2)6/40 (15)4/40 (10)3/24 (12.5)Carboplatin+docetaxel0/29 (0)0/28 (0)1/26 (3.8)1/27 (3.7)1/27 (3.7)3/28 (10.7)2/28 (7.1)0/28 (0)0/28 (0)0/27 (0)WHO-CIPN ^2^\
(\> = grade 1)Docetaxel1/122 (0.8)3/122 (2.7)5/109 (4.6)8/105 (7.6)11/95 (11.6)7/41 (17.1)5/38 (13.2)16/96 (16.7)15/89 (16.9)9/84 (10.7)Paclitaxel2/33 (6.1)9/33 (27.3)10/31 (32.3)16/31 (51.6)16/28 (57.1)0/18 (0)7/13 (53.8)14/27 (51.9)8/21 (38.1)2/15 (13.3)Cisplatin/Carboplatin1/80 (1.2)2/65 (3)6/57 (10.5)3/46 (6.5)1/32 (3.1)0/9 (0)0/6 (0)2/43 (4.7)1/39 (2.6)1/32 (3.1)Oxaliplatin2/28 (7.1)6/26 (23.1)9/25 (36)14/22 (63.6)12/22 (54.5)9/16 (56.3)3/11 (27.3)4/21 (19)6/17 (35.3)1/12 (8.3)Carboplatin+paclitaxel2/49 (4)11/44 (25)12/42 (28.6)15/42 (35.7)19/38 (50)13/30 (43.3)5/19 (20.8)7/40 (17.5)7/40 (17.5)1/24 (4.2)Carboplatin+docetaxel0/29 (0)0/28 (0)0/26 (0)0/27 (0)1/27 (3.7)2/28 (7.1)3/28 (10.7)2/28 (7.1)0/28 (0)0/27 (0)Cotton wool(+)^3^Docetaxel1/113 (0.9)2/104 (1.9)2/104 (1.9)2/100 (1.2)1/84 (1.2)1/38 (2.6)2/31 (6.5)6/82 (7.3)4/64 (6.3)2/57 (3.5)Paclitaxel0/31 (0)3/33 (9.1)1/29 (3.4)5/29 (17.2)0/28 (0)2/18 (11.1)1/13 (7.7)7/25 (28)7/20 (35)2/14 (14.3)Cisplatin/Carboplatin0/65 (0)1/55 (1.8)0/48 (0.0)0/43 (0)0/16 (0)0/8 (0)0/3 (0)1/29 (3.4)2/26 (7.7)0/19 0)Oxaliplatin0/27 (0)3/25 (12.0)3/25 (12)5/22 (22.7)3/16 (18.8)2/12 (16.7)8/20 (40)3/16 (18.8)1/12 (8.3)1/12 (8.3)Carboplatin+paclitaxel0/49 (0)6/36 (8.3)4/35 (11.4)8/36 (22.2)6/29 (17.1)4/27 (14.8)1/20 (5)6/33 (18.2)4/31 (12.9)0/16 (0)Carboplatin+docetaxel0/29 (0)0/28 (0)0/26 (0)0/27 (0)0/27 (0)1/28 (3.6)1/28 (3.6)1/28 (3.6)0/26 (0)0/25 (0)Monofilame-nt(+)^3^Docetaxel1/116 (0.9)2/109 (1.8)4/109 (3.7)5/105 (4.8)7/88 (8)5/41 (12.2)5/31 (16.1)16/85 (18.8)12/68 (17.6)4/57 (7.0)Paclitaxel1/33 (3.0)9/33 (27.3)3/31 (9.7)5/31 (16.1)0/31 (0)1/18 (5.6)1/13 (7.7)7/27 (25.9)8/21 (38.1)3/15 (20.0)Cisplatin/Carboplatin0/77 (0)1/63 (1.6)2/57 (3.5)2/46 (4.3)1/17 (5.9)1/9 (0)0/3 (0)3/33 (9.1)3/29 (10.3)0/21 (0)Oxaliplatin0/28 (0)2/26 (7.7)3/25 (12)4/22 (18.2)2/22 (9.1)3/16 (18.8)1/11 (9.1)7/21 (33.3)4/17 (23.5)1/12 (8.3)Carboplatin+paclitaxel0/49 (0)4/43 (9.3)6/42 (14.3)11/42 (26.2)11/38 (28.9)9/30 (30)4/20 (20)10/38 (26.3)7/35 (20)2/17 (11.8)Carboplatin+docetaxel0/29 (0)0/28 (0)0/26 (0)0/27 (0)1/27 (3.7)2/28 (7.1)3/28 (10.7)2/28 (7.1)0/26 (0)0/25 (0)FACTGOG-Ntx\
Numbness/tingling in hands ^5^\
(\>grade = 1)Docetaxel21/122 (17.2)20/113 (17.7)26/109 (23.9)29/105 (27.6)36/96 (37.5)19/41 (46.3)17/38 (44.7)41/96 (42.7)36/90 (40)22/84 (26.2)Paclitaxel7/33 (21.2)11/32 (34.4)13/31 (41.9)15/31 (41.9)13/28 (48.4)8/18 (44.4)9/13 (69.2)17/27 (63)11/21 (52.4)10/15 (66.7)Cisplatin/Carboplatin11/81 (13.6)7/66 (10.6)9/57 (15.8)9/47 (19.1)6/32 (18.7)2/9 (22.2)3/6 (50)11/43 (25.6)7/39 (17.9)3/32 (9.4)Oxaliplatin2/28 (7.1)10/24 (41.7)15/26 (65.2)15/20 (75)15/20 (75)8/14 (57.1)5/9 (55.6)15/21 (71.4)11/17 (64.7)10/12 (83.3)Carboplatin+paclitaxel5/50 (10)23/44 (52.4)25/41 (61.0)22/41 (53.7)22/37 (59.5)18/28 (64.3)13/25 (52)22/40 (55)16/40 (40)8/25 (32)Carboplatin+docetaxel1/29 (3.4)1/28 (3.6)5/26 (19.2)3/27 (11.1)4/27 (14.8)8/28 (28.6)12/28 (42.9)10/28 (35.7)6/28 (21.4)5/27 (18.5)FACTGOG-Ntx Numbness/tingling in feet ^5^\
(\>grade = 1)Docetaxel6/122 (4.9)10/113 (8.8)12/109 (11)22/105 (21)29/96 (30.2)12/41 (29.3)9/38 (23.7)37/96 (38.5)31/90 (34.4)21/84 (25.0)Paclitaxel5/32 (15.6)11/31 (35.5)13/31 (41.9)15/31 (8.4)14/28 (50)8/18 (44.4)7/13 (53.8)16/27 (59.3)10/21 (47.6)7/15 (46.7)Cisplatin/Carboplatin5/81 (6.2)7/66 (10.6)5/57 (8.8)7/47 (14.9)7/32 (21.9)3/9 (33.3)3/6 (50)14/43 (32.6)8/39 (20.5)2/32 (6.2)Oxaliplatin2/28 (7.2)9/27 (37.5)16/23 (69.6)13/20 (65)15/20 (75)8/14 (57.1)3/9 (33.3)15/21 (71.4)5/21 (23.8)9/12 (75.0)Carboplatin+paclitaxel5/50 (10)20/44 (45.5)22/41 (53.7)26/41 (63.4)23/37 (62.2)20/28 (71.4)13/25 (52)26/40 (75)19/40 (47.5)8/25 (32)Carboplatin+docetaxel1/29 (3.4)2/28 (7.1)4/26 (15.4)5/27 (18.5)6/27 (22.2)8/28 (28.6)13/28 (46.4)10/28 (35.7)6/28 (21.4)5/27 (18.5)ECIPN-20 (item 3) Numbness inhands/fingers ^4^\
(\> = grade 2)Docetaxel26/122 (21.3)22/113 (19.5)24/109 (22)31/105 (29.5)36/96 (37.5)17/41 (41.5)18/38 (47.4)41/96 (42.7)36/89 (40.4)25/84 (29.8)Paclitaxel6/33 (18.2)11/31 (35.5)13/31 (41.9)14/31 (45.2)13/28 (46.4)6/18 (33.3)10/13 (76.9)10/27 (59.3)10/21 (47.6)8/15 (53.3)Cisplatin/Carboplatin12/81 (14.8)5/66 (7.6)9/57 (15.8)9/47 (19.1)6/32 (18.7)3/9 (33.3)3/6 (50)11/43 25.6)8/39 (20.5)4/32 (22.5)Oxaliplatin6/28 (21.4)14/24 (58.8)17/23 (73.9)14/20 (70.0)14/20 (70.0)8/14 (57.1)6/9 (66.6)14/21 (66.7)10/17 (38.1)8/12 (66.7)Carboplatin+paclitaxel5/50 (10)20/44 (45.5)22/41 (53.7)23/41 (56.1)23/37 (62.2)15/28 (53.6)13/24 (54.2)22/40 (55)16/40 (40)10/25 (40)Carboplatin+docetaxel2/29 (6.9)2/28 (7.1)4/26 (15.4)4/27 (14.8)4/27 (14.8)7/28 (25)11/28 (39.3)9/28 (32.1)7/28 (25)6/27 (22.2)ECIPN-20 (item 4) Numbness in feet/toes ^4^\
(\> = grade 2)Docetaxel8/122 (6.6)12/113 (10.6)15/109 (13.8)23/105 (21.9)30/96 (31.2)10/41 (24.4)11/38 (29.0)37/96 (38.5)31/90 (34.4)24/84 (28.6)Paclitaxel7/33 (21.2)12/32 (37.5)11/31 (35.5)11/31 (35.5)14/28 (50.0)9/18 (50.0)8/13 (61.5)15/27 (55.6)6/15 (40)Cisplatin/Carboplatin8/81 (9.9)4/66 (6.1)6/57 (10.5)7/47 (14.9)5/32 (15.6)3/9 (33.3)3/6 (50)11/43 (25.6)9/39 (23.1)3/32 (9.4)Oxaliplatin3/28 (10.7)10/24 (41.7)14/9 (60.1)14/20 (70.0)14/20 (70)7/14 (50.0)4/9 (44.4)13/21 (61.9)10/17 (58.8)8/12 (66.7)Carboplatin+paclitaxel7/50 (14)23/44 (52.3)21/41951.2)24/41 (58.5)25/37 (67.6)20/28 (71.4)15/24 (62.5)27/40 (67.5)21/40 (52.5)11/25 (440Carboplatin+docetaxel2/29 (6.9)2/28 (7.1)3/26 (11.5)4/27 (14.8)6/27 (22.2)8/28 (28.6)13/28 (46.4)10/28 (35.7)6/28 (21.4)5/27 (18.5)^1^NCI motor/sensory (\>grade 2 = Moderate symptoms limiting instrumental ADL); ^2^ WHO CIPN (\> = Grade 1 = Paresthesias and/or decreased tendon reflexes); ^3^ cotton wool/monofilament (+) = (abnormal sensation, a lot/a little/no sensation); ^4^ ECIPN-20 (\> = grade 2 = A little); ^5^ FACTGOG-Ntx (\> = 1 = a little bit)Fig. 5**a**. Chemotherapy-induced peripheral neuropathy prevalence over time in patients receiving Docetaxel (*n* = 122, 901 assessments) **b**. Chemotherapy-induced peripheral neuropathy prevalence over time in patients receiving Paclitaxel (*n* = 33, 245 assessments) **c**. Chemotherapy-induced peripheral neuropathy prevalence over time in patients receiving Cisplatin/Carboplatin (*n* = 80, 409 assessments) **d**. Chemotherapy-induced peripheral neuropathy prevalence over time in patients receiving Oxaliplatin (*n* = 28, 200 assessments) **e**. Chemotherapy-induced peripheral neuropathy prevalence over time in patients receiving Carboplatin+Docetaxel (*n* = 29, 274 assessments) **f**. Chemotherapy-induced peripheral neuropathy prevalence over time in patients receiving Carboplatin+Paclitaxel (*n* = 49, 357 assessments)

Cumulative chemotherapy dose and CIPN {#Sec12}
-------------------------------------

Figures [6](#Fig6){ref-type="fig"}a-e show the dose-response relationship in different chemotherapy agents. No relationship was found for CIPN increases relative to the agent's cumulative dose (Table [4](#Tab4){ref-type="table"}). In most agents CIPN was established early in the treatment and continued to increase or remained relatively stable irrespective of the cumulative dose. This analysis was followed by a segmented regression for each chemotherapy agent, and again this showed no cumulative dose relationship with CIPN, with the exception of cisplatin-based regimens (=362 observations). In the latter, the turning point for motor CIPN (using CTCAE) was a dose of 249 mg/m2 (*p* \< 0.001) and for sensory CIPN was 234 mg/m2 (*p* \< 0.05), with lower cumulative dose than the turning point being linked with lower CIPN, and higher cumulative dose than the turning point not being associated with any higher CIPN.Fig. 6**a**. Dose-response relationship related to NCI CTCAE-motor dysfunction scale with oxaliplatin, carboplatin (AUC), cisplatin, paclitaxel and docetaxel respectively **b**. Dose-response relationship related to NCI CTCAE-sensory dysfunction scale with oxaliplatin, carboplatin (AUC), cisplatin, paclitaxel and docetaxel respectively **c**. Dose-response relationship related to the WHO neuropathy scale with oxaliplatin, carboplatin (AUC), cisplatin, paclitaxel and docetaxel respectively 6 **d**. Dose-response relationship related to cotton wool assessment with oxaliplatin, carboplatin (AUC), cisplatin, paclitaxel and docetaxel respectively **e**. Dose-response relationship related to monofilament assessment with oxaliplatin, carboplatin (AUC), cisplatin, paclitaxel and docetaxel respectivelyTable 4Odds ratios of the increased risk of developing neuropathy per 100 mg unit increase (or 1 AUC for carboplatin) of chemotherapy dose (generalized estimating equation)AbnormalDrugNCI CTCAE motorNCI CTCAE sensoryWHO CIPNCotton woolMonofilamentOxaliplatin-based regimens (*n* = 27, observations = 196)1.15 (0.90, 1.47)1.25 (0.94, 1.67)1.13 (0.95, 1.34)1.32\* (1.06, 1.64)1.42\* (1.06, 1.89)Carboplatin AUC (in 1 unit) (*n* = 88, observations = 657)1.03 (0.98, 1.08)1.06\* (1.01, 1.10)0.98 (0.93, 1.03)0.93\* (0.88, 0.99)0.96 (0.92, 1.01)Cisplatin-based regimens (*n* = 70, observations = 362)0.89 (0.55, 1.46)0.90 (0.55, 1.49)1.43 (0.94, 2.19)1.28 (0.57, 2.91)1.37 (0.86, 2.17)Paclitaxel-based regimens (*n* = 83, observations = 621)1.02 (0.83, 1.25)1.01 (0.85, 1.20)1.01 (0.92, 1.11)0.91 (0.80, 1.04)0.94 (0.84, 1.06)Docetaxel-based regimens (*n* = 151, observations = 1167)0.96 (0.69, 1.32)1.03 (0.69, 1.52)1.36 (0.91, 2.04)2.12 (0.93, 4.81)1.47 (0.96, 2.25)\*Significant at 5% level

Correlations between scales {#Sec13}
---------------------------

Among the four clinician-based diagnostic scales, correlations were moderate to low at best. Often scales were not correlated with each other, and they were showing somewhat stronger correlations in later assessments, when CIPN was more well-established. The WHO criterion had correlations of r~s~ = 0.21--0.37 (p \< 0.001) with the other scales at baseline and highest at 9-month (r~s~ = 0.44--0.65, *p* \< 0.001) and 12-month (r~s~ = 0.40--0.59, *p* \< 0.001) assessment. The WHO criterion was correlated more with the (sensory) monofilament assessment (r~s~ = 0.21--0.68, *p* \< 0.001) and had low to moderate correlations (r~s~ = 0.15, *p* \< 0.05 - r~s~ = 0.48, *p* \< 0.001) with the sensory CIPN CTCAE.

Nerve conduction study (NCS) {#Sec14}
----------------------------

Patients treated with taxane chemotherapy showed a substantial decrease in SNAP (sensory) amplitudes at NCS~end~ (35.52 ± 4.48% lesser compared to NCS~baseline~). Specifically, the SNAP amplitudes of the upper limbs were affected nearly twice as much as the lower limbs (42.79 ± 3.90% and 26.71 ± 8.45% lower than NCS~baseline~, respectively). In contrast, the cMAP (motor) amplitudes of the lower limbs showed substantial decrease at NCS~end~, compared to the upper limbs (17.42 ± 6.51% and 1.87 ± 2.23% lower than NCS~baseline~, respectively). Compared to the amplitudes, the sensory and motor velocities displayed a minor decrease at NCS~end~ (1.54 ± 2.52% and 2.05 ± 1.63% lower than NCS~baseline~, respectively) (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7Changes observed in chemotherapy-induced peripheral neuropathy through Nerve Conduction Studies. The graph values correspond to the average of percentage differences to baseline (pre-NCS) of post-NCS and recovery-NCS

At 3 months post chemotherapy, i.e. NCS~3m~, patients continued to demonstrate a large decrease in SNAP amplitudes (a further decrease of 7.79 ± 7.05% lower than NCS~end~). It is to be noted that the upper limbs (4.85 ± 8.15% lower than NCS~end~) had better recovery compared to the lower limbs (18.33 ± 13.97% lower than NCS~end~). On the other hand, the SNAP velocities had negligible improvement (0.69 ± 2.78% lower than NCS~end~). The cMAP amplitudes, showed a recovery at NCS~3m~ (4.34 ± 3.05% higher than NCS~end~). The upper limbs did not exhibit much change (0.48 ± 2.03% lower than NCS~end~), while the lower limbs showed a considerable increase in NCS value (39.41 ± 16.28% higher than NCS~end~). Similar to the NCS~3m~ trend of the SNAP amplitudes, the motor velocities suffered a large deterioration (8.24 ± 3.91% lower than NCS~end~), with the upper limbs (6.54 ± 3.99% lower than NCS~end~) better than the lower limbs (20.28 ± 14.07% compared to lower than NCS~end~) (Fig. [7](#Fig7){ref-type="fig"}).

Discussion {#Sec15}
==========

The current study is the largest and one of a few longitudinal assessments of CIPN (2399 observations) using a heterogeneous population that increases the generalizability of the results. It showed that prevalence was significantly different from measure to measure used, patient reported outcome measures (through quality of life scales) consistently showed much higher CIPN rates than clinician-based or objective measures, and with highest rates in patients receiving taxanes (primarily paclitaxel). Cumulative dose was not linked with higher CIPN prevalence, but time since starting chemotherapy was. Correlations among scales were generally low, although these increased in the later assessments primarily among sensory neuropathy assessments. NCS data confirmed the sensory and motor impairment of participants.

This study confirms that there is wide variation of CIPN prevalence between scales. This is supported by a meta-analysis of CIPN prevalence studies, where confidence intervals were high (i.e. at 3 months CIs = 37--84%) \[[@CR3]\]. CIPN prevalence is reported in the literature to be high, from 54 to 73% in some studies \[[@CR31]--[@CR33]\] but often studies are using patient-reported outcome measures to assess prevalence, where CIPN prevalence is not the primary objective. Even in our study, when patient-reported outcome measures were used, prevalence doubled or tripled from that identified by other measures. It remains to be seen if such measures are appropriate diagnostic tools, as they also include items related to autonomic changes; such changes may have pre-existed the chemotherapy and it is unclear if they represent true CIPN-related changes or they are unrelated symptoms, particularly as many of the reporting studies are cross-sectional in nature. In our data, about one-quarter of the patients reported symptoms in the EORTC quality of life CIPN subscales at baseline, before they received any chemotherapy (Table [3](#Tab3){ref-type="table"}). Nevertheless, other studies show similar results with our study including a one-year cumulative prevalence of 28.7% \[[@CR34]\], 23% in a sample of patients receiving docetaxel \[[@CR7]\] and 14.1% at 1 year \[[@CR35]\]. Thus, it is clear that if we focus on prevalence rates that do not derive from patient-reported outcome measures, then prevalence is generally lower to about 15--25% of patients, the severity is generally not high, and that patient-reported outcome measures may overestimate CIPN prevalence as they include symptoms that may have pre-existed the chemotherapy. If patient-reported outcome measures, which are generally used to assess the 'impact' of a symptom on patients' lives rather than diagnose a condition, are used to show CIPN prevalence, it has to focus more clearly on symptomatology that has developed after the use of chemotherapy, and exclude those that had similar symptoms before the chemotherapy. The latter number we have seen in our study was as high as 21.2%. Hence, cross-sectional assessments of CIPN using such patient-reported outcome measures can overestimate its prevalence. Irrespective of prevalence rates, however, the impact of the presence of such symptoms is significant \[[@CR4], [@CR6]--[@CR10], [@CR36]\] and every effort should be made to improve the patient symptom experience.

The issue of reliable and valid measurement of CIPN is fundamental, and based on the (relatively low) correlations between scales shown in this study, it may be that each scale measures a different phenomenon or the scales used in this study were not all sensitive enough to detect CIPN. Which scale from the available ones is best for clinical assessment remains to be identified, and perhaps there is a need for a combination of scales to be used \[[@CR37]\]. In our study, the cotton wool assessment led to the lowest 'pick up' rates and at a later time from all other scales suggesting this may not be an appropriate and sensitive enough test. The WHO criterion and the monofilament were highly correlated, suggesting that the former measures more sensory changes. However, the WHO criterion is minimally used in current practice. Abnormalities in vibration and monofilament examinations are associated with abnormal sural nerve amplitudes \[[@CR38]\] and hence monofilament may be a useful method in identifying CIPN. The CTCAE is the only scale that assesses separately motor and sensory problems (alongside quality of life scales/ patient-reported outcome measures); while this is an important dimension, in our study the CTCAE identified less patients with CIPN than other scales, suggesting that it may not have high sensitivity. Generally speaking, CIPN is not assessed properly and we should focus more on improving its assessment \[[@CR6]\].

A recent review \[[@CR39]\] suggests that CIPN is a predominantly sensory symptom with pain; however, in our study we obsered a considerable prevalence of motor neuropathy, particularly in the docetaxel subgroup, across assessments as well as paclitaxel and paclitaxel/carboplatin in the later assessments. This finding should be interpreted with caution as the only motor neuropathy-specific scale we used was the CTCAE item, and the literature suggests that the CTACE motor item overestimates its occurrence, possibly as a result of confounding factors \[[@CR40]\] although NCS data confirms motor impairment in this sample (suggested by the decreased motor nerve amplitude in our sample). Also, it is unclear whether the motor dysfunction observed is true motor neuropathy or fine motor impairments secondary to sensory loss, which is difficult to distinguish when 'blunt' instruments such as the CTC are used. Motor dysfunction has been shown in a small-scale study, where decreased superexcitability of motor axons was reported \[[@CR41]\]. Furthermore, a neurophysiological study in children receiving vincristine showed impaired myotatic reflexes and motor neural impairment \[[@CR42]\] and a larger study in oxaliplatin-treated patients found no nerve dysfunction before the initiation of chemotherapy \[[@CR43]\] while others studies (ie. ref. \[[@CR38]\]) have focused on sensory subclinical changes only. NCS focusing on motor nerves, in addition to sensory nerves, could highlight if the above comment is correct, and Kandula et al. \[[@CR44]\] review the diagnostic role of NCS in CIPN. It may be that there is a general impression that CIPN is mainly sensory impairment as most of the studies in the past assessed sensory problems, with little assessment of motor problems. Motor symptoms may also be hidden under 'fatigue' too, and 'feeling weak' may be interpreted as tired rather than myopathy. Also, it is common in clinical practice to only ask patients if they have any numbness or tingling in the hands/feet, again focusing only on sensory symptoms. There is a need to focus more concretely on the assessment of motor symptoms in the future, as they are also linked with significant impact in daily activities, and define CIPN more broadly as a motor and sensory impairment accompanied by autonomic system manifestations.

Furthermore, pain was not a major issue and occurred in less than one-quarter of the participants, whereas tingling and numbness were most prevalent in more than half the sample. Pain may be more prevalent in oxaliplatin \[[@CR45], [@CR46]\] or paclitaxel-based chemotherapy but it seems to be less common in other taxane- or platinum-based chemotherapies \[[@CR47]\]. Whether autonomic symptoms are the result of CIPN or symptoms reflecting other pre-existing conditions before chemotherapy treatment is not clear as yet, and more prospective work needs to be done in this area too. Also, many other symptoms were reported by patients at different degrees in each type of chemotherapy suggesting that CIPN is not the same symptom across taxanes and platins. This is an important finding to consider particularly when we assess patients or when therapeutic trials for CIPN (in terms of primary outcome) are planned.

At the 12-month assessment, a significant number (around 8% through objective and physician-based scales or 25--30% based on the patient-reported outcome measure) remained with CIPN symptoms, similar or somewhat lower to other studies in the past \[[@CR7], [@CR34], [@CR35], [@CR48]\]. As CIPN has been seen in patients even 11--12 years after chemotherapy \[[@CR10], [@CR49]\], it seems that this group of patients may experience chronic and long-lasting CIPN.

Cumulative dose of the chemotherapy was not a predictive factor for CIPN, against the currently held belief, in any of the chemotherapy regimens we assessed. An increasing body of literature shows similar results \[[@CR31], [@CR50]\]. This brings into question the current practice \[[@CR51], [@CR52]\] of dose reductions or chemotherapy discontinuation in patients experiencing CIPN. This finding, alongside with the key factor of time since chemotherapy, suggests that from the moment CIPN is experienced, it will continue to increase for the next few months and carry its course before we see any noticeable decreases after 6 months, irrespective of dose of chemotherapy \[[@CR53]\], and patients may continue developing CIPN over time even if doses are reduced \[[@CR54]\]. Whether treatment discontinuation or dose reductions have a real impact on decreasing CIPN should be assessed in future research.

Limitations of the study include the decrease in the sample over cycles (many patients did not complete more than 3--4 cycles or were ill/dead, giving significant missing data particularly in the 5th--6th cycle data. Some chemotherapy protocols also had a relatively small sample size. Where numbers were small, results should be interpreted with caution. Interrater reliability of the assessments may be an issue, although specific training and a protocol guide was provided to all assessors. The sample from Caucasians was also small compared to the Chinese and other Asian sample included. Some of the assessments used (i.e. WHO criterion; cotton wool) have not been rigorously evaluated as assessment methods in the CIPN context) and hence interpretation of results from these scales should be cautious. Cotton wool test and 10 g monofilament can detect sensory impairment, but they are unable to capture deep sensory impairment. This is typical of platinum drugs neuropathy and might partly explain why they are performing less efficiently than tuning fork examination in comparison with literature data.

Conclusions {#Sec16}
===========

This study maps the development and progression of CIPN in patients receiving taxane- and platinum-based chemotherapy, showing distinct CIPN profiles. It shows a lower level of CIPN than previously reported with significant differences among different chemotherapy protocols and scales used to measure CIPN. It brings into question the sensitivity and/or appropriateness of scales currently used to measure CIPN. Nevertheless, CIPN is a clinical problem present even 1 year after treatments and needs careful clinical attention. Practice-important findings include that early CIPN predicts CIPN in subsequent cycles, and this is the case irrespective of cumulative dose of chemotherapy. More work is needed in ascertaining best assessment methods for clinical practice and the findings call for a re-think of current clinical practices.

We thank all the patients for their participation in the study.

Funding {#FPar1}
=======

This study was supported by a Polytechnic University Direct grant (in HK) and an NCIS Seed Funding Grant, National Medical Research Council (Singapore).

Availability of data and materials {#FPar2}
==================================

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Conception of the study: AM, LKPS. Development of study protocol: AM, VL, JSKA, KTL, YCL, KHW, RS. Participant recruitment: HLC, JSKA, KTL, YCL, KHW, CF, RS. Participant follow-up and assessment: HLC, VL, AC, CWC, JY, CF, RS. Nerve Conduction Studies: AC, AB, RS. Data analysis: AM, HLC, VL, AC, AB, RS. Contribution to writing the paper including discussion: all. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

The study has been approved by the ethics committees of the Hong Kong Polytechnic University, Hong Kong; Central Cluster of the Hospital Authority, Hong Kong; The National University Hospital; Singapore; The University of Manchester, Manchester, UK; and the Central Manchester Research and Ethics Committee. All participants have provided written informed consent.

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
